These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7520935)

  • 1. Pharmacologic treatment of thalassemia intermedia with hydroxyurea.
    Hajjar FM; Pearson HA
    J Pediatr; 1994 Sep; 125(3):490-2. PubMed ID: 7520935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
    Karimi M; Mohammadi F; Behmanesh F; Samani SM; Borzouee M; Amoozgar H; Haghpanah S
    Eur J Haematol; 2010 Jan; 84(1):52-8. PubMed ID: 19799627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia.
    Hoppe C; Vichinsky E; Lewis B; Foote D; Styles L
    Am J Hematol; 1999 Dec; 62(4):221-7. PubMed ID: 10589077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematological responses to hydroxyurea therapy in multitransfused thalassemic children.
    Choudhry VP; Lal A; Pati HP; Arya LS
    Indian J Pediatr; 1997; 64(3):395-8. PubMed ID: 10771862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea in thalassemia intermedia--a promising therapy.
    Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea therapy in thalassemia.
    Loukopoulos D; Voskaridou E; Stamoulakatou A; Papassotiriou Y; Kalotychou V; Loutradi A; Cozma G; Tsiarta H; Pavlides N
    Ann N Y Acad Sci; 1998 Jun; 850():120-8. PubMed ID: 9668534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term hydroxyurea therapy in beta-thalassaemia patients.
    de Paula EV; Lima CS; Arruda VR; Alberto FL; Saad ST; Costa FF
    Eur J Haematol; 2003 Mar; 70(3):151-5. PubMed ID: 12605659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.
    Bradai M; Abad MT; Pissard S; Lamraoui F; Skopinski L; de Montalembert M
    Blood; 2003 Aug; 102(4):1529-30. PubMed ID: 12702505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
    El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
    Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to hydroxyurea therapy in beta-thalassemia.
    Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
    Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea in the management of thalassemia intermedia.
    Karimi M
    Hemoglobin; 2009; 33 Suppl 1():S177-82. PubMed ID: 20001623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/beta-thalassemia.
    Rigano P; Manfré L; La Galla R; Renda D; Renda MC; Calabrese A; Calzolari R; Maggio A
    Hemoglobin; 1997 May; 21(3):219-26. PubMed ID: 9140718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
    Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
    Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
    Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
    Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary report: hydroxyurea produces significant clinical response in thalassemia intermedia.
    Styles L; Lewis B; Foote D; Cuda L; Vichinsky EP
    Ann N Y Acad Sci; 1998 Jun; 850():461-2. PubMed ID: 9668584
    [No Abstract]   [Full Text] [Related]  

  • 19. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients.
    Rigano P; Pecoraro A; Calzolari R; Troia A; Acuto S; Renda D; Pantalone GR; Maggio A; Di Marzo R
    Br J Haematol; 2010 Dec; 151(5):509-15. PubMed ID: 20955403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients.
    Watanapokasin Y; Chuncharunee S; Sanmund D; Kongnium W; Winichagoon P; Rodgers GP; Fucharoen S
    Exp Hematol; 2005 Dec; 33(12):1486-92. PubMed ID: 16338491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.